Strafford will be offering a webinar/teleconference entitled "Hedge Fund IPR Challenges to Pharma Patents: Latest Developments and Strategies to Strengthen Patents -- Lessons From PTAB Denial of Acorda Therapeutics IPR, Celgene's Sanctions Motion, and More" on October 12, 2015 from 1:00 to 2:30 pm (EDT). Rekha Bansal, Sr. Director of IP, Principia Biopharma; Thomas L. Irving, Dr. Amanda K. Murphy, Ph.D., and Barbara R. Rudolph, Ph.D. of Finnegan Henderson Farabow Garrett & Dunner will provide patent counsel with guidance on the recent inter partes review (IPR) challenges by hedge funds to pharmaceutical patents, examining the patents that are being attacked and the grounds for attack, discuss the lessons learned from these challenges, and will offer strategies for strengthening patents to withstand attack. The webinar will review the following questions:
• What types of pharma patents are being challenged by hedge funds in IPR?
• What grounds are being asserted?
• What can be learned from the PTAB's Aug. 24, 2015, decision declining to institute two hedge fund IPRs?
• What message is the PTAB sending by choosing not to take a position on whether a third party’s filing status is determinative of a petition’s ability to be taken up?
• What can the pharma patent owner do to strengthen their patents to enhance the chance of survival in IPR, irrespective of the identity of the petitioner?
The registration fee for the webinar is $297 ($362 for registration and CLE processing). Those interested in registering for the webinar, can do so here.
Comments